Trial Profile
Randomized phase II study for treatment optimization of the treatment of prostate cancer hormonrefraktaren with docetaxel + prednisone versus docetaxel + prednisone + low-dose cyclophosphamide [Randomisierte Phase II Studie zur Therapieoptimierung der Behandlung des hormonrefraktaren Prostatakarzinoms mit Docetaxel + Prednison versus Docetaxel + Prednison + low dose Cyclophosphamid]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2013
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 30 Aug 2011 New trial record